Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026

Same author

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026

Same author

Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma.

Cancer research communications·2026

Same author

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Blood advances·2026

Same author

Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.

Oncology and therapy·2026

Same author

Prospective Pilot Study of <sup>11</sup>C-acetate and <sup>18</sup>F-FDG with PET/CT and PET/MRI for Lesion Detection in Multiple Myeloma.

Molecular imaging and biology·2026

Search research articles

Related Experiment Video

Updated: May 2, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Hyperdiploid myeloma: The silent majority.

J Erin Wiedmeier-Nutor¹, Rafael Fonseca¹

¹Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona, USA.

British Journal of Haematology

|June 10, 2025

Summary

This summary is machine-generated.

Hyperdiploid multiple myeloma (Hy-MM), a common subtype, is often overlooked. Further research is crucial for developing targeted therapies and improving patient outcomes in this group.

Keywords:

aneuploidy hyperdiploid multiple myeloma

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Related Experiment Videos

Last Updated: May 2, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Area of Science:

Oncology
Hematology
Genetics

Background:

Hyperdiploid multiple myeloma (Hy-MM) accounts for 50% of all multiple myeloma cases.
Hy-MM is characterized by trisomies of odd-numbered chromosomes (excluding 13 and 17), resulting in an average of 53 chromosomes.
This prevalent subtype receives less attention than high-risk multiple myeloma variants.

Purpose of the Study:

To highlight the prevalence and under-recognition of Hy-MM.
To underscore the need for further investigation into Hy-MM.
To emphasize the potential for targeted therapies and personalized treatment strategies.

Main Methods:

This study is a review and synthesis of existing literature on Hy-MM.
Analysis of cytogenetic data characterizing Hy-MM.
Comparative analysis of Hy-MM with other multiple myeloma subtypes.

Main Results:

Hy-MM is a common but frequently under-recognized subtype of multiple myeloma.
The defining cytogenetic feature is the presence of multiple trisomies of odd-numbered chromosomes.
Despite its prevalence, Hy-MM is less studied compared to other subtypes.

Conclusions:

Gaps in understanding Hy-MM necessitate continued research.
Advancing knowledge of Hy-MM can lead to improved targeted therapies.
Personalized treatment strategies are essential for improving outcomes in Hy-MM patients.